孟鲁司特钠联合酮替芬治疗咳嗽变异性哮喘69例疗效评价

Observation on Effect of Montelukast Sodium plus Ketotifen in Treating Cough Variant Asthma in 69 Cases

目的观察孟鲁司特钠联合酮替芬治疗咳嗽变异性哮喘的临床疗效及安全性。方法将2010年2月至2014年2月收治的138例患者随机分为观察组和对照组,每组69例。对照组给予酮替芬治疗,观察组给予孟鲁司特钠联合酮替芬治疗。治疗1个月后评价两组临床疗效及不良反应发生情况。结果观察组和对照组总有效率分别为95.65%和75.36%,观察组明显优于对照组(P<0.05);治疗后观察组用力肺活量(FVC)、呼气峰流速(PEF)及第1秒用力呼气容积占用力肺活量比(FEV1/FVC)等肺功能指标与治疗前相比明显改善,且显著优于对照组(P<0.05);观察组症状缓解时间及消失时间明显短于对照组(P<0.05);两组不良反应发生率未见明显差异(P>0.05)。结论孟鲁司特钠联合酮替芬可有效改善咳嗽变异性哮喘患者的临床症状,疗效确切,具有良好的安全性,值得临床推广。

Objective To observe the clinical efficacy and safety of montelukast sodium plus ketotifen in the treatment of cough variant asthma. Methods 138 cases of cough variant asthma in our department from February 2010 to February 2014 were randomly divided into the observation group and control group with 69 cases in each group. The control group received the ketotifen treatment, while the observation group was given the treatment of montclukast sodium plus ketotifen. The clinical effects and the occurrence of adverse reac- tions after 1 month treatment were evaluated in the two groups. Results The total effective rates after therapy in the observation group and the control group were 95.65% and 75.36% respectively, the observation group was significantly superior to the control group with statistical difference（P〈 0. 05）. The lung function indexes of FVC, PEF and FEV1/FVC after treatment in the observation group were significantly improved compared with before treatment（ P 〈 0. 05） and significantly superior to the control group（ P 〈 0.05）; the time of symptoms alleviation and symptoms disappearance in the observation group were significantly shorter than those in the control group with statistical differences. There was no statistically significant difference in the occurrence rate of complications between the two groups （P 〉 0.05）. Conclusion Montelukast sodium plus Ketotifen has definite effect and good safety in treating cough variant asthma, which is worthy of being widely promoted in clinical practice.